MacroGenics

$22.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.26 (-5.32%) As of 4:41 PM UTC today

Why Robinhood?

You can buy or sell MacroGenics and other stocks, options, and ETFs commission-free!

About MGNX

MacroGenics, Inc. Common Stock, also called MacroGenics, is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD. The listed name for MGNX is MacroGenics, Inc. Common Stock.

CEO

Scott E. Koenig

Employees

384

Headquarters

Rockville, Maryland

Founded

2000

Market Cap

1.25B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

433.40K

High Today

$24.26

Low Today

$22.16

Open Price

$23.72

Volume

140.48K

52 Week High

$32.18

52 Week Low

$4.04

Collections

Analyst Ratings

73%

of 11 ratings

Buy

73%

Hold

Sell

18%

MGNX Earnings

-$1.02

-$0.68

-$0.34

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 23, After Hours